Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FWD1802 in ER+/HER2- advanced breast cancer
NCT06064812Phase 2Recruiting
- Start
- Sep 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fwd1802 in estrogen receptor-positive breast cancer (ER+) (2 arms). Primary endpoints: Maximum Tolerated Dose at 2 years, Recommended Phase II Dose at 2 years and 1 more. Started Sep 2023; status: recruiting.
02
Drugs
fwd1802
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT06064812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06064812.